Abbott's Humira Letter Needed FDA's Green Light, Jury Told
At a trial over claims that AbbVie Inc. and Abbott Laboratories failed to warn about Humira's risks, an AbbVie regulatory director testified Thursday that Abbott needed regulatory approval before it could...To view the full article, register now.
Already a subscriber? Click here to view full article